Dr. Harish Bhaskar, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 511
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
FL license ME98387
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ascension St Vincent's Riverside Jacksonville, FL
- Ascension St Vincent's Southside Jacksonville, FL
- Ascension St Vincent's Clay County Middleburg, FL
- Ascension St Vincent's St Johns County St. Johns, FL
Medical groups
- St Vincent's Ambulatory Care Inc (310 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 511
- Services billed
- 1,184
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 192 | 136 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 128 | 73 |
| Test to examine how well the lungs exchange gases | 115 | 115 |
| Test to determine lung volumes using sensors | 114 | 114 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 109 | 67 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 105 | 105 |
| Critical care, first 30-74 minutes | 73 | 29 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 69 | 66 |
| Test to measure rate of airflow | 69 | 69 |
| Established patient office or other outpatient visit, 20-29 minutes | 35 | 33 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Jacksonville, FL | 390 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Jacksonville, FL | 273 |
| Opsumit (macitentan) | 189 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Jacksonville, FL | 132 |
| Montelukast Sodium Other prescribers in Jacksonville, FL | 127 |
| Adempas (riociguat) | 121 |
| Prednisone Other prescribers in Jacksonville, FL | 89 |
| Azithromycin Other prescribers in Jacksonville, FL | 88 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Jacksonville, FL | 84 |
| Roflumilast Other prescribers in Jacksonville, FL | 75 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 8 payments worth $411 in total to this clinician.
| Insmed, Inc. | $173 |
|---|---|
| Verona Pharma, Inc. | $125 |
| Pulmonx Corporation | $46.60 |
| Actelion Pharmaceuticals US, Inc. | $44.45 |
| GlaxoSmithKline, LLC. | $21.72 |
| Food and Beverage | $411 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $58,993 in research payments for these studies, mostly to the institutions running them.
- Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
United Therapeutics Corporation · Enrolling by invitation · NCT04905693 - Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation · Completed · NCT04708782
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.